Boehringer Ingelheim GmbH
Leoforos Andrea Syngrou 340, 176 73 Kallithea, Greece
Award: Boehringer Ingelheim is Global Top Employer 2021
- Boehringer Ingelheim is one of sixteen top employers worldwide
- Awards in 27 countries and in Europe and the Latin America and Asia-Pacific regions
- Boehringer Ingelheim performs particularly well in strategy, corporate culture and employee involvement
The Top Employers Institute awarded Boehringer Ingelheim for the first time as a “Global Top Employer”, one of the world’s 16 best employers. The award shows that the research-driven pharmaceutical company is strongly oriented to the needs and well-being of its employees. Boehringer Ingelheim has been listed among the top employers in many countries and regions for the past seven years. This year, Boehringer Ingelheim will receive the award in 27 countries, as well as in Europe and the Latin America and Asia-Pacific regions. The independent Top Employers Institute certifies employers worldwide who wish to offer their employees excellent working conditions and support their development. Certification is based on a multi-level program to examine human resources management with detailed final feedback.
Compared to its competitors, the company particularly impressed with its successful long-term strategic orientation, as well as with a modern management culture and successful communication with employees. The Top Employers Institute also highlighted the strong, inclusive corporate culture. All of this leads to close ties and loyalty among employees and to the company.
An example of employee orientation is the flexible working environment. In this area, the already well-established mobile working helped, among other, to ensure that during the COVID pandemic, employees were able to quickly adapt their work to health protection requirements and to ensure business continuity from their homes. Another point mentioned by the jury relates to the ethical, inclusive approach to corporate decisions and a clear focus on the transfer and application of company values. In addition to the traditional pharmaceutical business, successful initiatives such as Making More Health (MMH) at Boehringer Ingelheim help to continuously improve health care worldwide, for example by encouraging social entrepreneurs. The family business also takes care of individual development opportunities through tailor-made education and training programs throughout the employee’s working life.
Exploring new avenues is deeply embedded in the corporate culture of the research-driven pharmaceutical company, as exemplified by the recent cooperation with Google on quantum computing for pharmaceutical drug research, announced in January. For 135 years, Boehringer Ingelheim has been creating values for human and animal health through innovation.
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim has remained an independent, family-owned company. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need in which we can make a real difference.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation to create the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of future next medical breakthroughs that will transform the lives of patients now, and in generations to come.
More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report:
Article and photo source: